Document is current

Article History

Received: 6 December 2024

Accepted: 17 December 2024

First Online: 26 May 2025

Acknowledgements

: We would like to extend our sincere gratitude to the external reviewers (S. A. Antoniou, Papageorgiou General Hospital, Greece; G. Leontiadis, McMaster University, Canada; E. Mannucci, University of Florence, Italy; F. Rutters, Amsterdam University Medical Center, Netherlands) for their valuable feedback and expertise, which significantly contributed to the development of the present SOP document.

: No additional data were generated or analysed in the preparation of this manuscript.

: This work received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

: AA has received grants or contracts from Boehringer Ingelheim, outside the submitted work. AA holds the Keenan Chair in Medicine at St. Michael’s Hospital and University of Toronto. MJD has received grants or contracts from AstraZeneca, Boehringer Ingelheim and Novo Nordisk, and consulting fees from Boehringer Ingelheim, Lilly, Novo Nordisk and Sanofi, outside the submitted work. MJD has received payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from AstraZeneca, Boehringer Ingelheim, Lilly and Sanofi, outside the submitted work. MJD has participated on a data safety monitoring board or advisory board for Amgen, AstraZeneca, Biomea Fusion and Zealand Pharma, outside the submitted work. Her institution has received payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from Novo Nordisk, and has participated on a data safety monitoring board or advisory board for Carmot/Roche, Regeneron and Sanofi, outside the submitted work. SDP has received consulting fees from Abbott, Altimmune, Amarin, Biomea Fusion, Eli Lilly, Eva Pharma, Menarini International, Novo Nordisk, Sanofi and Sun Pharma, outside the submitted work. SDP has received payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Laboratori Guidotti, Menarini International, Merck Sharpe & Dohme, Novo Nordisk and Sanofi, outside the submitted work. SDP has participated on a data safety monitoring board or advisory board for Applied Therapeutics and Eli Lilly, outside the submitted work. SDP served as President of the EASD/EFSD from 2020 to 2022 and has served as President of the European Diabetes Forum since 2023 and as President of the Fondazione Menarini. SFD has received honoraria for speaking at conferences from the American Association of Clinical Endocrinology and the National Institute for Prevention and Cardiovascular Health (Ireland), and has participated in a Trial Steering Committee for the NIHR, outside the submitted work. SFD has served as National Lead for the PPI Ignite Network (Ireland) since 2021 and was the National Lead for the National Clinical Programme for Diabetes (HSE) from 2016 to 2022. His institution has received research grants from the Health Research Board (Ireland), outside the submitted work. CM is the President of the EASD. CM serves or has served on the advisory panel for Novo Nordisk, Sanofi, Eli Lilly, Novartis, Boehringer Ingelheim, Roche, Medtronic, Imcyse, Insulet, Biomea Fusion and Vertex, outside the submitted work. Financial compensation for these activities has been received by KU Leuven. KU Leuven has received research support for CM from Medtronic, Imcyse, Novo Nordisk, Sanofi and ActoBio Therapeutics, outside the submitted work. CM serves or has served on the speakers’ bureau for Novo Nordisk, Sanofi, Eli Lilly, Medtronic and Boehringer Ingelheim. Financial compensation for these activities has been received by KU Leuven. DM has received unrestricted project financial support from Abbott and Dexcom, consulting fees from Amarna Therapeutics, Ferrer, Lilly, Novo Nordisk and Sanofi, and payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from Abbott, Amgen, Medtronic, AstraZeneca, Lilly, Menarini, Novo Nordisk and Sanofi, outside the submitted work. TT has received payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from Eli Lilly, Novo Nordisk, MSD, Merck, AstraZeneca, Boehringer Ingelheim, Swixx, Servier, Worwag and Medtronic, and support for attending meetings or travel from Novo Nordisk, Boehringer Ingelheim and AstraZeneca, outside the submitted work. TT has participated on an advisory board for Eli Lilly, Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Merck and Pfizer, outside the submitted work. RIGH is the Chair of the EASD Committee on Clinical Affairs. RIGH has received fees for lecturing from Boehringer Ingelheim, EASD, Eli Lilly, Encore, Liberum, Novo Nordisk and ROVI, and funding for conference attendance from Novo Nordisk and Eli Lilly, outside the submitted work. AT is the Chair of the EASD Guidelines Oversight Committee. AT has received support for attending meetings and/or economy travel from Bayer, Menarini and Novo Nordisk, outside the submitted work. All authors are members of the EASD Guidelines Oversight Committee. The authors declare that there are no other relationships or activities that might bias, or be perceived to bias or influence the submitted work.

: TK and AT wrote the first manuscript draft. All authors edited the final manuscript draft. All authors significantly contributed to the manuscript and approved the final version for publication. TK and AT are the guarantors of this work.